STAMFORD, Conn., Nov. 21 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. announced that it has received a Canadian patent for its novel system, the Delcath system, used to deliver high doses of chemotherapy to specific organs and body regions.
The Canadian patent (CA 2297080) confirms that the Delcath system is a novel apparatus, and method for isolating blood flow within the pelvic cavity of a patient, allowing a high concentration of a chemotherapeutic agent to be administered without contaminating the rest of the patient’s blood circulatory system. The patent is similar to the patent the Company already holds in the United States, patent # 5,817,046.
“We are pleased that the Canadian patent office has issued Delcath a patent for our chemotherapy delivery system. This patent strengthens the Company’s intellectual property portfolio on an international basis. Delcath has received 11 patents worldwide, including the United States, Europe, Asia and Canada,” said M.S. Koly, Delcath’s Chief Executive Officer. “We are convinced that once we receive final FDA approval, our system will become the industry standard for treating advanced stage liver cancer.”
In May of 2005, Delcath received fast-track status from the U.S. FDA for treating metastatic melanoma in the liver with melphalan, a currently approved anticancer agent. The FDA fast-track program is designed to facilitate development and expedite the review of new drugs or, in the case of Delcath, a new drug-device combination, having the potential to treat illnesses, which currently lack adequate therapy.
About Delcath
Delcath is a developer of isolated perfusion technology for organ or region-specific delivery of therapeutic agents. Six U.S. and three foreign issued patents cover its technology. The company is headquartered in Stamford, CT.
This release contains “forward-looking statements” based on current expectations but involving known and unknown risks and uncertainties. Actual results or achievements may be materially different from those expressed or implied. Delcath plans and objectives are based on assumptions involving judgments with respect to future economic, competitive and market conditions, its ability to consummate, and the timing of, acquisitions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond its control. Therefore, there can be no assurance than any forward-looking statement will prove to be accurate.
Delcath Systems, Inc.
CONTACT: M. S. Koly, Chief Executive Officer of Delcath Systems, Inc.,+1-203-323-8668; or Todd Fromer, +1-212-896-1215, tfromer@kcsa.com, MichaelCimini, +1-212-896-1233, mcimini@kcsa.com, or Lewis Goldberg,+1-212-896-1216, lgoldberg@kcsa.com, all of KCSA Worldwide for DelcathSystems, Inc.
Web site: http://www.delcath.com/
